Table 3.
Treatment frequency and its number of eyes
| Overall | 2010–2012 | 2011–2013 | 2012–2014 | 2013–2015 | 2014–2016 | 2015–2017 | P value for ANOVA | P value for trend test | |
| Anti-VEGF | n=1234 (60.2%) |
n=80 (58.8%) |
n=107 (37.5%) |
n=201 (55.1%) |
n=324 (58.8%) |
n=343 (73.3%) |
n=179 (73.4%) |
<0.001 | <0.001 |
| Number of times | 3.8±3.3 | 2.5±1.8 | 1.8±1.5 | 2.9±2.7 | 3.5±3.0 | 4.7±3.7 | 5.5±3.6 | <0.001 | <0.001 |
| Bevacizumab | n=635 (31.0%) |
n=80 (58.8%) |
n=103 (36.1%) |
n=180 (49.3%) |
n=224 (40.7%) |
n=37 (7.9%) |
n=11 (4.5%) |
<0.001 | <0.001 |
| Number of times | 2.2±2.0 | 2.5±1.7 | 1.6±0.9 | 2.4±2.3 | 2.4±2.2 | 1.9±1.3 | 1.3±0.5 | 0.003 | 0.969 |
| Ranibizumab | n=578 (28.2%) |
n=2 (1.5%) |
n=4 (1.4%) |
n=44 (12.1%) |
n=152 (27.6%) |
n=284 (60.7%) |
n=92 (37.7%) |
<0.001 | <0.001 |
| Number of times | 3.3±2.8 | 1.0 | 1.0±0.0 | 2.1±1.6 | 2.9±2.3 | 3.4±3.1 | 4.2±2.8 | <0.001 | <0.001 |
| Aflibercept | n=336 (16.4%) |
n=1 (0.7%) |
n=4 (1.4%) |
n=14 (3.8%) |
n=69 (12.5%) |
n=139 (29.7%) |
n=109 (44.7%) |
<0.001 | <0.001 |
| Number of times | 4.1±3.0 | 2.0 | 5.0±4.1 | 3.5±2.8 | 2.4±1.9 | 4.0±2.9 | 5.4±3.3 | <0.001 | <0.001 |
| Corticosteroid | n=1077 (52.6%) |
n=66 (48.5%) |
n=145 (50.9%) |
n=195 (53.4%) |
n=345 (62.6%) |
n=220 (47.0%) |
n=106 (43.4%) |
<0.001 | 0.137 |
| Number of times | 2.0±1.3 | 1.9±1.2 | 2.0±1.3 | 2.1±1.3 | 2.0±1.4 | 2.2±1.4 | 1.7±1.1 | 0.097 | 0.517 |
| Intravitreal TA | n=162 (7.9%) |
n=8 (5.9%) |
n=4 (1.4%) |
n=42 (11.5%) |
n=66 (12.0%) |
n=28 (6.0%) |
n=14 (5.7%) |
<0.001 | 0.466 |
| Number of times | 1.7±1.1 | 1.4±0.7 | 2.0±0.8 | 1.5±0.7 | 1.6±1.2 | 2.4±1.5 | 1.7±1.1 | 0.014 | 0.034 |
| Subtenon TA | n=966 (47.1%) |
n=62 (45.6%) |
n=144 (50.5%) |
n=167 (45.8%) |
n=288 (52.3%) |
n=205 (43.8%) |
n=100 (41.0%) |
0.020 | 0.094 |
| Number of times | 2.0±1.3 | 1.9±1.2 | 2.0±1.2 | 2.0±1.4 | 2.1±1.3 | 2.0±1.2 | 1.6±1.0 | 0.022 | 0.117 |
| Macular PC | n=746 (36.4%) |
n=40 (29.4%) |
n=122 (42.8%) |
n=141 (38.6%) |
n=236 (42.8%) |
n=154 (32.9%) |
n=53 (21.7%) |
<0.001 | <0.001 |
| Number of times | 1.9±1.4 | 1.7±1.1 | 1.9±1.4 | 2.0±1.4 | 1.8±1.3 | 2.0±1.6 | 1.3±0.6 | 0.010 | 0.339 |
| Vitrectomy | n=597 (29.1%) |
n=64 (47.1%) |
n=125 (43.9%) |
n=115 (31.5%) |
n=148 (26.9%) |
n=76 (16.2%) |
n=69 (28.3%) |
<0.001 | <0.001 |
| Number of times | 1.1±0.3 | 1.1±0.3 | 1.1±0.3 | 1.1±0.2 | 1.0±0.2 | 1.0±0.2 | 1.1±0.2 | 0.558 | 0.221 |
Data about number of times were presented as mean value ±SD.
ANOVA, analysis of variance; PC, photocoagulation; TA, triamcinolone acetonide; VEGF, vascular endothelial growth factor.